僅用于工業(yè)應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Mitazalimab （ADC-1013; JNJ-64457107） is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells （DC）, to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment